23 results
DEFM14A
LABP
Landos Biopharma Inc
25 Apr 24
Proxy related to merger
5:07pm
’ qualifications, experience and reputation in the biopharmaceutical industry and in connection with strategic transactions involving public companies, and noted … the following related factors:
the business reputation and capabilities of AbbVie, including AbbVie’s track record of successfully completing merger
PREM14A
LABP
Landos Biopharma Inc
15 Apr 24
Preliminary proxy related to merger
5:18pm
, 2023. The Board of Directors considered Jefferies’ qualifications, experience and reputation in the biopharmaceutical industry and in connection … is achieved within the time period described therein, including the following related factors:
the business reputation and capabilities of AbbVie, including
DEFA14A
LABP
Landos Biopharma Inc
25 Mar 24
Additional proxy soliciting materials
9:19am
that is not a stock transfer agent of national reputation or the corporate trust department of a commercial bank.
(d) The Rights Agent will reasonably cooperate
8-K
EX-2.1
LABP
Landos Biopharma Inc
25 Mar 24
AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
8:54am
of national reputation or the corporate trust department of a commercial bank.
(d) The Rights Agent will reasonably cooperate with Parent and any successor
PRE 14A
d8n7ftr9 6m81j8zed
10 Apr 23
Preliminary proxy
4:20pm
DEF 14A
6i8i4wj3imc2us5
28 Apr 22
Definitive proxy
4:16pm
10-K
efzmx 4vz
31 Mar 21
Annual report
5:03pm
424B4
yzou5
4 Feb 21
Prospectus supplement with pricing info
5:02pm
S-1/A
dbfbm9u94i13ha
28 Jan 21
IPO registration (amended)
9:12am
S-1
jodn9a7s4ds0e57zlbj
13 Jan 21
IPO registration
5:07pm
S-1
EX-10.4
j9zjp9ejjyy
13 Jan 21
IPO registration
5:07pm
DRS/A
EX-10.4
b15 as31yc
1 Dec 20
Draft registration statement (amended)
12:00am